Inactive Instrument

CymaBay Therapeutics, Inc.

Equities

CBAY

US23257D1037

Biotechnology & Medical Research

CymaBay Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022

August 11, 2022 at 04:04 pm EDT

CymaBay Therapeutics, Inc. reported earnings results for the second quarter and six months ended June 30, 2022. For the second quarter, the company reported net loss was USD 27.09 million compared to USD 23.22 million a year ago. Basic loss per share from continuing operations was USD 0.31 compared to USD 0.34 a year ago.
For the six months, net loss was USD 54.86 million compared to USD 40.77 million a year ago. Basic loss per share from continuing operations was USD 0.62 compared to USD 0.59 a year ago.

Latest news about CymaBay Therapeutics, Inc.

Gilead Sciences Completes $4.3 Billion Cymabay Acquisition	Mar. 22	MT
CymaBay Therapeutics, Inc. Announces Board Changes	Mar. 22	CI
CymaBay Therapeutics, Inc.(NasdaqGS:CBAY) dropped from NASDAQ Composite Index	Mar. 21	CI
Gilead Sciences, Inc. completed the acquisition of CymaBay Therapeutics, Inc..	Mar. 21	CI
CymaBay Therapeutics, Inc.(NasdaqGS:CBAY) dropped from S&P Pharmaceuticals Select Industry Index	Mar. 21	CI
CymaBay Therapeutics, Inc.(NasdaqGS:CBAY) dropped from S&P TMI Index	Mar. 21	CI
CymaBay Therapeutics, Inc.(NasdaqGS:CBAY) dropped from S&P Global BMI Index	Mar. 21	CI
CymaBay Therapeutics, Inc.(NasdaqGS:CBAY) dropped from NASDAQ Biotechnology Index	Mar. 14	CI
Gilead Sciences Says Antitrust Waiting Period for CymaBay Therapeutics Deal Expires	Mar. 11	MT
CymaBay Says European Medicines Agency to Review Marketing Authorization Application for Seladelpar	Mar. 04	MT
CymaBay Therapeutics, Inc. Announces European Medicines Agency Accepts for Review the Marketing Authorization Application for Seladelpar for the Treatment of Primary Biliary Cholangitis	Mar. 04	CI
CymaBay Therapeutics, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	Feb. 28	CI
CymaBay Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Feb. 28	CI
Leerink Partners Downgrades CymaBay Therapeutics to Market Perform From Outperform, Adjusts PT to $32.50 From $26	Feb. 20	MT
UBS Downgrades CymaBay Therapeutics to Neutral From Buy, Adjusts Price Target to $32.50 From $25	Feb. 14	MT
LifeSci Capital Downgrades CymaBay Therapeutics to Market Perform From Outperform	Feb. 14	MT
Piper Sandler Downgrades CymaBay Therapeutics to Neutral From Overweight, Adjusts PT to $32.50 From $33	Feb. 14	MT
North American Morning Briefing :Stock Futures -2-	Feb. 14	DJ
B. Riley Downgrades CymaBay Therapeutics to Neutral From Buy on Heels of Announced Sale to Gilead Sciences, Raises PT to $32.50 From $29	Feb. 13	MT
B. Riley Downgrades CymaBay Therapeutics to Neutral From Buy	Feb. 13	MT
JonesTrading Downgrades CymaBay Therapeutics to Hold From Buy	Feb. 13	MT
Cantor Fitzgerald Downgrades CymaBay Therapeutics to Neutral From Overweight, Adjusts PT to $32.50 From $30	Feb. 13	MT
William Blair Downgrades CymaBay Therapeutics to Market Perform From Outperform	Feb. 13	MT
BTIG Downgrades CymaBay Therapeutics to Neutral From Buy	Feb. 13	MT
HC Wainwright Downgrades CymaBay Therapeutics to Neutral From Buy, Adjusts PT to $32.50 From $28	Feb. 13	MT

Chart CymaBay Therapeutics, Inc.

Duration

Period

More charts

Company Profile

CymaBay Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing therapies for patients with liver and other chronic diseases. The Company's lead product candidate, seladelpar (MBX-8025), is a potent and selective agonist of peroxisome proliferator-activated receptor delta (PPARd), a nuclear receptor that regulates genes directly or indirectly involved in the synthesis of bile acids/sterols, metabolism of lipids and glucose, inflammation and fibrosis. The Company is focused on developing seladelpar for the treatment of primary biliary cholangitis (PBC), an autoimmune disease that causes progressive destruction of the bile ducts in the liver resulting in impaired bile flow (cholestasis) and inflammation.

Sector

Biotechnology & Medical Research

Related indices

Russell 2000

More about the company

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
VERTEX PHARMACEUTICALS INCORPORATED	-2.06%	104B
REGENERON PHARMACEUTICALS, INC.	+1.74%	97.42B
ARGENX SE	+0.79%	22.2B
BIONTECH SE	-17.64%	21.23B
GENMAB A/S	-11.11%	18.33B
WUXI APPTEC CO., LTD.	-42.83%	16.35B
BEIGENE, LTD.	-17.71%	15.06B
NEUROCRINE BIOSCIENCES, INC.	+3.80%	13.98B
SAREPTA THERAPEUTICS, INC.	+33.26%	11.66B

Bio Therapeutic Drugs